Emergent Biosolutions (EBS) Stock: Buy, Sell, or Hold?
EBS - Emergent Biosolutions, Inc.
$6.23
0.36 (6.13%)
â˛
5d:
+0.0%
30d:
+36.92%
90d:
-25.74%
WAIT
LOW Confidence
Analysis Updated: Sep 11, 2026 12:00 AM ET
Earnings: Nov 04, 2026
Get Alerted When EBS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: EBS is fairly priced but lacks strong directional signals. At -22.4% expected growth, valuation appears cheap. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: EBS is fairly priced but lacks strong directional signals. At -22.4% expected growth, valuation appears cheap. Wait for clearer setup or better entry on dips.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$25.88
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$16.07
61.2% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 12.7x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: EBS is currently trading at $6.23, which is considered slightly high relative to its 30-day fair value range of $4.70 to $6.53. From a valuation perspective, the stock is trading at a discount (Forward PE: 6.0) compared to its historical average (12.7). Remarkably, the market is currently pricing in an annual earnings decline of 22.4% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, EBS is in a strong downtrend. Immediate support is located at $5.50, while resistance sits at $6.60. The stock is showing strong short-term momentum, up 6.1% recently.
Market Sentiment: EBS scores 37/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $11.00 (+76.6%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, EBS is in a strong downtrend. Immediate support is located at $5.50, while resistance sits at $6.60. The stock is showing strong short-term momentum, up 6.1% recently.
Market Sentiment: EBS scores 37/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $11.00 (+76.6%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$4.70 -
$6.53
Company Quality Score
42/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
47.6%
Protect Your Profits
Holding EBS? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BEARISH: Weak technical setup (37/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+6.1%)
- BULLISH: Trading 76.6% below Wall St target ($11.00)
- WARNING: Composite score 42/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$4.70 -
$6.53
Current vs Trading Range
SLIGHTLY HIGH
Support & Resistance Levels
Support Level
$5.50
Resistance Level
$6.60
Current Trend
Strong Downtrend
Technical data as of
Sep 11, 2026
Fundamental Context
Forward P/E (Next Year Est.)
5.95
Wall Street Target
$11.00
(+76.6%)
Revenue Growth (YoY)
66.3%
Earnings Growth (YoY)
-93.8%
Profit Margin
-23.0%
Valuation Discount vs History
-22.4% cheaper
PE vs Historical
6.0 vs 12.7
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-22.4%
(market-implied from PE analysis)
1-Year Target
$5.61
(-10%)
2-Year Target
$5.05
(-19%)
3-Year Target
$4.54
(-27%)
3-Yr Target (if PE normalizes)
(PE: 6â13)
$9.69
(+56%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 20.2, Growth: 191.0%)
$71.23
(+1043%)
Base:
(SPY PE: 6.0, Growth: 191.0%)
$21.03
(+238%)
Bear:
(PE: 5.1, Growth: 191.0%)
$17.87
(+187%)
đĄ
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 6.0 to 12.7
Stabilization Target:
$13.29
(+113.3%)
PE Expansion Potential:
+113.3%
Share & Embed Analysis
Last updated: September 13, 2026 11:37 AM ET
Data refreshes hourly during market hours. Next update: 12:37 PM
Data refreshes hourly during market hours. Next update: 12:37 PM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is EBS showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences IâĻ |
STRONG BUY
25 analysts |
$211 | 60 HOLD |
|
LQDA
Liquidia Technologies Inc |
STRONG BUY
10 analysts |
$108 | 70 BUY |
|
INDV
Indivior PLC Ordinary ShâĻ |
STRONG BUY
7 analysts |
$49 | 69 BUY |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$108 | 46 HOLD |
|
UTHR
United Therapeutics CorpâĻ |
STRONG BUY
15 analysts |
$664 | 47 HOLD |
Advanced EBS Option Strategies
Professional options setups generated by AI based on today's EBS price and gamma walls.
